Acute fulminant hepatitis after treatment with rabeprazole and terbinafine: is rabeprazole the culprit?
Andrade
Raúl J
RJ
Lucena
Maria Isabel
MI
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000208:Acute Disease; D001562:Benzimidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D001707:Biopsy, Needle; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology* / Q000473:pathology*; D004347:Drug Interactions; D005500:Follow-Up Studies; D006801:Humans; D009281:Naphthalenes / Q000009:adverse effects* / Q000627:therapeutic use; D009853:Omeprazole / Q000031:analogs & derivatives; D064750:Rabeprazole; D018570:Risk Assessment; D012720:Severity of Illness Index; D000077291:Terbinafine
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001562:Benzimidazoles; D009281:Naphthalenes; D064750:Rabeprazole; D000077291:Terbinafine; D009853:Omeprazole